ORAMED PHARMACEUTICALS INC.
Extracted from this filing and checked against the source text.
ORAMED PHARMACEUTICALS INC. terminated Controlled Equity Offering Agreement with Cantor Fitzgerald & Co. valued at Terminated with no penalties; prior net proceeds of $26.25 million (effective 2024-03-17).
On March 12, 2024, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) to terminate that certain Controlled Equity Offering Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald (the “Cantor Agreement”), effective as of March 17, 2024.View on SEC.gov
ORAMED PHARMACEUTICALS INC. entered into ATM Agreement with Rodman & Renshaw LLC and StockBlock Securities LLC valued at $75,000,000 maximum aggregate offering price (effective 2024-03-18).
On March 18, 2024, Oramed Pharmaceuticals Inc. (the “Company”) entered into an at the market offering agreement (the “ATM Agreement”) with Rodman & Renshaw LLC and StockBlock Securities LLC as sales agents (each, an “Agent” and together, the “Agents”), pursuant to which the Company may issue and sell in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), shares of its common stock, par value $0.012 per share, having a maximum aggregate offering price of up to $75,000,000 from time to time through the Agents.View on SEC.gov
556 material agreements filed in the last 30 days. Browse all material agreements →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.